"Yes. Yes." You say, "So?"
He's studying, among other things, Noonan Syndrome and the protein mutations thereof. Seriously! He's looking at how the genetic mutations affect the protein production and the resulting symptomology and diseases. He's also the researcher responsible for finding the SOS1 mutation now associated with NS.
"Yes. Yes." You say again, perhaps with a bit more interest... "So?"
What drew my attention was the final line of the bio on the Canada Research Chairs website:
By understanding the molecular mechanisms by which Shp2 [PTPN11] and SOS1 mutations cause diseases, Neel can work on treatments that reverse at least some of their harmful effects and lessen their impact on quality of life.Treatments!
The site bio is almost two years old. Feeling brave, and figuring I have nothing to lose and lots to gain, I sent an email asking for more information and hoping I didn't sound like a nut.
Within the hour, I had a response. After emailing back and forth I was able to clarify what information I was looking for (Quoted from my email):
If we were having coffee, I'd ask, quite simplistically, "How's it going? That working on treatments thing...? Any progress?"To which I received the following reply:
I'd follow up with, "Do you know if the amino acid/protein changes from RAF1 gene mutations are similar/the same as those of Shp2 and SOS1?"
As far as therapies go, it is too early to be sure. We know that the cardiac valve defects in Shp2/ptpn11-dependent NS are due to too much activation of the Erk1 kinase during development. But it is unclear whether this can be reversed post-birth, and unfortunately, we probably can't answer this using our mouse models because mice w/valve disease die right after birth.Isn't this exciting? Every time I read it my heart picks up.
We don't know yet whether the other problems (height, etc) are due to too much erk, but I suspect they are since our initial data on the raf mutants shows same effects as shp2 mutants.
We do have mouse models of raf1 mutants with increased and decreased kinase activity-and we know that they are not the same (the increased activity mutants cause decreased viability, the decreased mutants are normally viable, but they do have short stature). We don't know yet if the increased raf mutants cause hypertrophic cardiomyopathy (thick hearts) but if they do, we will test them with drugs that inhibit erk (actually, mek) activation to see if we can reverse the phenotype.
While it's unlikely we'll see solutions or treatments during the lifetime of our children, I can, at the very least, draw courage and hope from the simple fact that someone is actively working on my daughter's behalf. Researching to better her quality of life. And if not hers, than at least for someone.





